ROBERT KAPLAN: Open Payments
NPI 1124101035 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$495 in 19 payments from 9 companies in 2025. Trend: 2023 $763 · 2024 $1,251 · 2025 $495
Food & beverage: $495
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $179 |
| GlaxoSmithKline, LLC. | 3 | $84 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $58 |
| Exact Sciences Corporation | 2 | $41 |
| Amgen Inc. | 2 | $41 |
| Viatris Specialty LLC | 1 | $28 |
| CVRx, Inc. | 1 | $25 |
| Abbott Laboratories | 1 | $22 |
| Novo Nordisk Inc | 1 | $17 |
Products named: CAPLYTA, Kerendia, TRELEGY ELLIPTA, Cologuard Collection Kit, OTEZLA, SHINGRIX, YUPELRI, Barostim Neo System.
Industry payments across NV — which companies pay providers there.
